The combination of current standard-of-care therapy (radiation and temozolomide) with mIDH1 inhibitor and PD-L1–blocking ICI increased tumor regression of mIDH1 glioma–bearing mice, decreased T cell exhaustion, and favored the generation of memory CD8+ T cells (59). Here, CD8A is linked to glioma.